lactic acid has been researched along with Colitis in 26 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Colitis: Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclosporine A (CyA) is a useful immunosuppressive agent for steroid-dependent or steroid-refractory ulcerative colitis." | 7.77 | The effective therapy of cyclosporine A with drug delivery system in experimental colitis. ( Fukata, N; Fukui, T; Koyabu, M; Kusuda, T; Matsushita, M; Miyoshi, H; Nishio, A; Okazaki, K; Tabata, Y; Uchida, K, 2011) |
| " The present study is aimed at testing the hypothesis that resistant maltodextrin (RM), a soluble dietary fiber produced by starch debranching, alleviated dextran sulfate sodium- (DSS-) induced colitis in mice." | 3.96 | Resistant Maltodextrin Alleviates Dextran Sulfate Sodium-Induced Intestinal Inflammatory Injury by Increasing Butyric Acid to Inhibit Proinflammatory Cytokine Levels. ( Han, D; Huang, S; Pang, J; Wang, J; Wang, S; Wu, Y; Wu, Z; Zhang, S, 2020) |
| "Cyclosporine A (CyA) is a useful immunosuppressive agent for steroid-dependent or steroid-refractory ulcerative colitis." | 3.77 | The effective therapy of cyclosporine A with drug delivery system in experimental colitis. ( Fukata, N; Fukui, T; Koyabu, M; Kusuda, T; Matsushita, M; Miyoshi, H; Nishio, A; Okazaki, K; Tabata, Y; Uchida, K, 2011) |
| "Colitis is a common and complex intestinal inflammatory disease in which lactate, a metabolite of anaerobic glycolysis, plays a crucial role." | 1.91 | Dietary lactate supplementation can alleviate DSS-induced colitis in piglets. ( Chen, D; Fan, Z; He, J; Huang, Z; Luo, J; Luo, Y; Mao, X; Wang, M; Yan, H; Yu, B; Yu, J; Zheng, P, 2023) |
| "Chronic inflammation is a major driving factor for the development of colitis-associated cancer (CAC)." | 1.51 | ( Cao, G; Li, J; Li, Z; Shen, H; Xie, P; Yue, Z; Zang, T; Zhang, S; Zhu, Y, 2019) |
| "Colitis was induced on Day 35, the animals were sacrificed on Day 37." | 1.46 | Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis. ( Capron, M; Delbeke, M; Dendooven, A; Driss, V; Flament, MP; Karrout, Y; Priemel, PA; Siepmann, J; Thi, THH, 2017) |
| "Curcumin (CC) is an anti-inflammatory local agent, which presents poor ADME properties." | 1.40 | pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. ( Beloqui, A; Coco, R; des Rieux, A; Memvanga, PB; Préat, V; Ucakar, B, 2014) |
| "Colitis was induced by rectal instillation of trinitrobenzen sulfonic acid to male Wistar rats." | 1.38 | Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis. ( Abdolghaffari, AH; Abdollahi, M; Atyabi, F; Baeeri, M; Baghaei, A; Dinarvand, R; Fazeli, MR; Jamalifar, H; Mahbod, M; Mahdaviani, P; Mohammadirad, A; Saadatzadeh, A, 2012) |
| "Colitis was induced in mice by the intrarectal administration of trinitrobenzene sulfonic acid (TNBS)." | 1.38 | Prevention of trinitrobenzene sulfonic acid-induced experimental colitis by oral administration of a poly(lactic-coglycolic acid) microsphere containing prostaglandin E₂ receptor subtype 4 agonist. ( Okamoto, T; Tabata, Y; Uemoto, S, 2012) |
| "Acute colitis was induced with dextran sulfate sodium (DSS) for 7 days following administration of phosphate buffered saline for 7 days (DSS-treated group, n = 5)." | 1.36 | 1H NMR-based metabonomic assessment of probiotic effects in a colitis mouse model. ( Ahn, YT; Hong, YS; Huh, CS; Hwang, GS; Kim, DH; Lee, H; Lee, JH; Park, JC; Ryu, DH, 2010) |
| "Colitis was induced in BALB/c mice by 5% dextran sodium sulfate." | 1.31 | Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. ( Chiba, T; Ikada, Y; Kawanami, C; Matsushima, Y; Nakase, H; Ohana, M; Okazaki, K; Oshima, C; Tabata, Y; Uchida, K; Uose, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 8 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 1 |
| Li, R | 1 |
| Wang, Z | 1 |
| Zhang, Z | 1 |
| Wang, J | 2 |
| Qiao, Y | 1 |
| Huang, Y | 1 |
| Liu, W | 1 |
| Liu, J | 1 |
| Zhao, W | 1 |
| Li, C | 1 |
| Wu, T | 1 |
| Han, L | 1 |
| Hu, Z | 1 |
| Li, X | 1 |
| Zhou, J | 1 |
| Chen, X | 1 |
| Zhou, HC | 1 |
| Yu, WW | 1 |
| Yan, XY | 1 |
| Liang, XQ | 1 |
| Ma, XF | 1 |
| Long, JP | 1 |
| Du, XY | 1 |
| Mao, HY | 1 |
| Liu, HB | 1 |
| Taylor, SJ | 3 |
| Winter, MG | 3 |
| Gillis, CC | 3 |
| Silva, LAD | 3 |
| Dobbins, AL | 3 |
| Muramatsu, MK | 3 |
| Jimenez, AG | 3 |
| Chanin, RB | 3 |
| Spiga, L | 3 |
| Llano, EM | 3 |
| Rojas, VK | 3 |
| Kim, J | 3 |
| Santos, RL | 3 |
| Zhu, W | 3 |
| Winter, SE | 3 |
| Wang, M | 1 |
| Fan, Z | 1 |
| Chen, D | 1 |
| Yu, B | 1 |
| He, J | 1 |
| Yu, J | 1 |
| Mao, X | 1 |
| Huang, Z | 1 |
| Luo, Y | 1 |
| Luo, J | 1 |
| Yan, H | 1 |
| Zheng, P | 1 |
| Runge, KE | 1 |
| Bak, M | 1 |
| Vestergaard, A | 1 |
| Staerk-Østergaard, J | 1 |
| Jacobsen, S | 1 |
| Pihl, TH | 2 |
| Liu, S | 1 |
| Yan, W | 1 |
| Lv, Q | 1 |
| Yang, L | 1 |
| Miao, Y | 1 |
| Hu, Y | 1 |
| Wei, Z | 1 |
| Wang, S | 1 |
| Zhang, S | 2 |
| Huang, S | 1 |
| Wu, Z | 1 |
| Pang, J | 1 |
| Wu, Y | 1 |
| Han, D | 1 |
| Thi, THH | 1 |
| Priemel, PA | 1 |
| Karrout, Y | 1 |
| Driss, V | 1 |
| Delbeke, M | 1 |
| Dendooven, A | 1 |
| Flament, MP | 1 |
| Capron, M | 1 |
| Siepmann, J | 1 |
| Ranganathan, P | 1 |
| Shanmugam, A | 1 |
| Swafford, D | 1 |
| Suryawanshi, A | 1 |
| Bhattacharjee, P | 1 |
| Hussein, MS | 1 |
| Koni, PA | 1 |
| Prasad, PD | 1 |
| Kurago, ZB | 1 |
| Thangaraju, M | 1 |
| Ganapathy, V | 1 |
| Manicassamy, S | 1 |
| Naeem, M | 1 |
| Bae, J | 1 |
| Oshi, MA | 1 |
| Kim, MS | 1 |
| Moon, HR | 1 |
| Lee, BL | 1 |
| Im, E | 1 |
| Jung, Y | 1 |
| Yoo, JW | 1 |
| Li, J | 1 |
| Xie, P | 1 |
| Zang, T | 1 |
| Shen, H | 1 |
| Cao, G | 1 |
| Zhu, Y | 1 |
| Yue, Z | 1 |
| Li, Z | 1 |
| Sipola, S | 1 |
| Syrjälä, H | 1 |
| Koivukangas, V | 1 |
| Laurila, JJ | 1 |
| Ohtonen, P | 1 |
| Saarnio, J | 1 |
| Ala-Kokko, TI | 1 |
| Beloqui, A | 1 |
| Coco, R | 2 |
| Memvanga, PB | 1 |
| Ucakar, B | 1 |
| des Rieux, A | 1 |
| Préat, V | 2 |
| Wei, L | 1 |
| Zhou, Y | 1 |
| Yao, J | 1 |
| Qiao, C | 1 |
| Ni, T | 1 |
| Guo, R | 1 |
| Guo, Q | 1 |
| Lu, N | 1 |
| Frede, A | 1 |
| Neuhaus, B | 1 |
| Klopfleisch, R | 1 |
| Walker, C | 1 |
| Buer, J | 1 |
| Müller, W | 1 |
| Epple, M | 1 |
| Westendorf, AM | 1 |
| Ali, H | 1 |
| Weigmann, B | 1 |
| Collnot, EM | 1 |
| Khan, SA | 1 |
| Windbergs, M | 1 |
| Lehr, CM | 1 |
| Beharrysingh, R | 1 |
| McDaniel, JL | 1 |
| Abdel Hak, A | 1 |
| Voore, N | 1 |
| Abandeh, FI | 1 |
| Petersen, MB | 1 |
| Tolver, A | 1 |
| Husted, L | 1 |
| Tølbøll, TH | 1 |
| Del Carmen, S | 1 |
| de Moreno de LeBlanc, A | 1 |
| LeBlanc, JG | 1 |
| Hong, YS | 1 |
| Ahn, YT | 1 |
| Park, JC | 1 |
| Lee, JH | 1 |
| Lee, H | 1 |
| Huh, CS | 1 |
| Kim, DH | 1 |
| Ryu, DH | 1 |
| Hwang, GS | 1 |
| Fukata, N | 1 |
| Uchida, K | 2 |
| Kusuda, T | 1 |
| Koyabu, M | 1 |
| Miyoshi, H | 1 |
| Fukui, T | 1 |
| Matsushita, M | 1 |
| Nishio, A | 1 |
| Tabata, Y | 3 |
| Okazaki, K | 2 |
| Saadatzadeh, A | 1 |
| Atyabi, F | 1 |
| Fazeli, MR | 1 |
| Dinarvand, R | 1 |
| Jamalifar, H | 1 |
| Abdolghaffari, AH | 1 |
| Mahdaviani, P | 1 |
| Mahbod, M | 1 |
| Baeeri, M | 1 |
| Baghaei, A | 1 |
| Mohammadirad, A | 1 |
| Abdollahi, M | 1 |
| Okamoto, T | 1 |
| Uemoto, S | 1 |
| Plapied, L | 1 |
| Pourcelle, V | 1 |
| Jérôme, C | 1 |
| Brayden, DJ | 1 |
| Schneider, YJ | 1 |
| Nakase, H | 1 |
| Uose, S | 1 |
| Ohana, M | 1 |
| Matsushima, Y | 1 |
| Kawanami, C | 1 |
| Oshima, C | 1 |
| Ikada, Y | 1 |
| Chiba, T | 1 |
26 other studies available for lactic acid and Colitis
| Article | Year |
|---|---|
Lactate-utilizing bacteria ameliorates DSS-induced colitis in mice.
Topics: Adult; Animals; Bacteria; Colitis; Dextran Sulfate; Dysbiosis; Fecal Microbiota Transplantation; Fec | 2022 |
Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders.
Topics: Apoptosis; Caco-2 Cells; Cell Survival; Colitis; Cytokines; Deoxyglucose; Dextran Sulfate; Gastric M | 2021 |
Lactate-driven macrophage polarization in the inflammatory microenvironment alleviates intestinal inflammation.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation; L | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Colonocyte-derived lactate promotes E. coli fitness in the context of inflammation-associated gut microbiota dysbiosis.
Topics: Animals; Colitis; Dysbiosis; Enterobacteriaceae; Escherichia coli; Gastrointestinal Microbiome; Infl | 2022 |
Dietary lactate supplementation can alleviate DSS-induced colitis in piglets.
Topics: Animals; Colitis; Colon; Cytokines; Dextran Sulfate; Dietary Supplements; Interleukin-10; Lactic Aci | 2023 |
Serum amyloid A does not predict non-survival in hospitalised adult horses with acute colitis.
Topics: Animals; Biomarkers; Colitis; Horse Diseases; Horses; Lactic Acid; Prognosis; Serum Amyloid A Protei | 2023 |
3, 3'-diindolylmethane, a natural aryl hydrocarbon receptor agonist, alleviates ulcerative colitis by enhancing "glycolysis-lactate-STAT3″ and TIP60 signals-mediated Treg differentiation.
Topics: Animals; Cell Differentiation; Colitis; Colitis, Ulcerative; Forkhead Transcription Factors; Glucose | 2023 |
Resistant Maltodextrin Alleviates Dextran Sulfate Sodium-Induced Intestinal Inflammatory Injury by Increasing Butyric Acid to Inhibit Proinflammatory Cytokine Levels.
Topics: Animals; Butyric Acid; Colitis; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Feces; Fe | 2020 |
Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis.
Topics: Animals; Colitis; Disease Models, Animal; Drug Delivery Systems; Drug Liberation; Female; Glutathion | 2017 |
GPR81, a Cell-Surface Receptor for Lactate, Regulates Intestinal Homeostasis and Protects Mice from Experimental Colitis.
Topics: Animals; Colitis; Cytokines; Disease Models, Animal; Female; Homeostasis; Lactic Acid; Macrophages; | 2018 |
Colon-targeted delivery of cyclosporine A using dual-functional Eudragit
Topics: Administration, Oral; Animals; Body Weight; Colitis; Colon; Cyclosporine; Cytokines; Drug Carriers; | 2018 |
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Colitis; Colorectal Neoplasms; Dextran Sulfate; Diet; Dis | 2019 |
Impact of preoperative organ failures on survival in intensive care unit patients with colectomy.
Topics: Adrenergic alpha-Agonists; Aged; Biomarkers; C-Reactive Protein; Colectomy; Colitis; Drug Administra | 2013 |
pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
Topics: Animals; Anti-Inflammatory Agents; Caco-2 Cells; Cell Line; Colitis; Colon; Curcumin; Dextran Sulfat | 2014 |
Lactate promotes PGE2 synthesis and gluconeogenesis in monocytes to benefit the growth of inflammation-associated colorectal tumor.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Colitis; Colorectal Neoplasms | 2015 |
Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo.
Topics: Animals; Calcium Phosphates; CD4-Positive T-Lymphocytes; Cell Line; Colitis; Colon; Cytokines; Dextr | 2016 |
Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
Topics: Animals; Anti-Inflammatory Agents; Budesonide; Colitis; Drug Carriers; Drug Delivery Systems; Drug L | 2016 |
A Break in the Wall: Stercoral Colitis.
Topics: Abdomen; Aged; Cervical Cord; Colitis; Confusion; Fatal Outcome; Fecal Impaction; Female; Hospice Ca | 2016 |
Repeated measurements of blood lactate concentration as a prognostic marker in horses with acute colitis evaluated with classification and regression trees (CART) and random forest analysis.
Topics: Acute Disease; Animals; Biomarkers; Blood Proteins; Calcium; Calcium Compounds; Colitis; Decision Tr | 2016 |
Development of a potential probiotic yoghurt using selected anti-inflammatory lactic acid bacteria for prevention of colitis and carcinogenesis in mice.
Topics: Animals; Carcinogenesis; Colitis; Colonic Neoplasms; Female; Fermentation; Humans; Intestines; Lacti | 2016 |
1H NMR-based metabonomic assessment of probiotic effects in a colitis mouse model.
Topics: Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Inflammation Mediators; Lactic Acid; Magn | 2010 |
The effective therapy of cyclosporine A with drug delivery system in experimental colitis.
Topics: Administration, Oral; Animals; Biocompatible Materials; Cell Line; Colitis; Cyclosporine; Cytokines; | 2011 |
Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis.
Topics: Animals; Chitosan; Colitis; Cytokines; Dexamethasone; Disease Models, Animal; Dose-Response Relation | 2012 |
Prevention of trinitrobenzene sulfonic acid-induced experimental colitis by oral administration of a poly(lactic-coglycolic acid) microsphere containing prostaglandin E₂ receptor subtype 4 agonist.
Topics: Administration, Oral; Animals; Apoptosis; CD4-Positive T-Lymphocytes; Cell Proliferation; Colitis; C | 2012 |
Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
Topics: Animals; Caco-2 Cells; Chitosan; Colitis; Cytokines; Dextran Sulfate; Drug Carriers; Ethylene Oxide; | 2013 |
Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy.
Topics: Administration, Oral; Animals; Body Weight; Colitis; Colon; Dexamethasone; Dextrans; Drug Delivery S | 2000 |